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Abstract 
Background: Although the use of induced blood stage malaria infection has proven to be a valuable tool for testing 
the efficacy of vaccines and drugs against Plasmodium falciparum, a limiting factor has been the availability of Good 
Manufacturing Practice (GMP)—compliant defined P. falciparum strains for in vivo use. The aim of this study was to 
develop a cost-effective method for the large-scale production of P. falciparum cell banks suitable for use in clinical 
trials.
Methods: Genetically-attenuated parasites (GAP) were produced by targeted deletion of the gene encoding the 
knob associated histidine rich protein (kahrp) from P. falciparum strain 3D7. A GAP master cell bank (MCB) was manu-
factured by culturing parasites in an FDA approved single use, closed system sterile plastic bioreactor. All components 
used to manufacture the MCB were screened to comply with standards appropriate for in vivo use. The cryopreserved 
MCB was subjected to extensive testing to ensure GMP compliance for a phase 1 investigational product.
Results: Two hundred vials of the GAP MCB were successfully manufactured. At harvest, the GAP MCB had a para-
sitaemia of 6.3%, with 96% of parasites at ring stage. Testing confirmed that all release criteria were met (sterility, 
absence of viral contaminants and endotoxins, parasite viability following cryopreservation, identity and anti-malarial 
drug sensitivity of parasites).
Conclusion: Large-scale in vitro culture of P. falciparum parasites using a wave bioreactor can be achieved under 
GMP-compliant conditions. This provides a cost-effective methodology for the production of malaria parasites suit-
able for administration in clinical trials.
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Background
The use of controlled human malaria infection (CHMI) 
for testing the efficacy of vaccines and drugs against Plas-
modium falciparum is now well established. Induced 
blood stage malaria (IBSM) infection was pioneered in 
the 1990s [1–3], and was subsequently refined [4–7]. A 
limiting factor in the IBSM system has been the restricted 
number of defined P. falciparum strains available. This is 
in part due to difficulties obtaining suitable material for 
IBSM studies. Until recently it has been necessary to rely 
on access to deliberately infected volunteers or malaria-
infected travellers returning from overseas. In both cases, 
ethical approval is required to collect, store and use this 
material and there are concerns about contaminating 
infectious agents.
A process for culturing sufficient volumes of P. falci-
parum in tissue culture flasks for in vitro production of 
Good Manufacturing Practice (GMP) grade blood stage 
malaria cell banks was recently described [8]. This pro-
vides a culture-based alternative to sourcing parasites 
from individuals who have either experimental or natu-
ral infection (travellers returning from malaria endemic 
areas). This allows more flexibility in that new banks 
can be created as required, and not only when a suitable 
donor becomes available. It also allows for tight control 
over all components used in the cell bank manufacture 
and ensures that cell banks are renewable resources.
However, bulk preparation of P. falciparum cultures is 
both time consuming and technically demanding; yields 
can be low and parasite quality can be variable when 
grown in static culture. Multiply-infected erythrocytes 
(containing two or more parasites) are also observed 
more frequently than in suspension cultures [9]. The 
presence of erythrocytes containing multiple parasites 
is undesirable for IBSM studies where the parasite dose 
should be carefully controlled.
Dalton et al. have developed a method for production 
of large scale suspension cultures of asexual and sexual 
blood stage P. falciparum using a wave bioreactor (Wave 
Bioreactor™ 20/50 EHT system) [9, 10]. Growth of P. 
falciparum in the wave bioreactor system is superior to 
static flask cultures because parasites retain synchrony 
over at least 3 cycles of invasion. Additionally, the devel-
opment of multiply infected erythrocytes is reduced; this 
was shown to be both consistent and reproducible [9, 
10]. Disposable plastic bioreactors also allow for care-
ful control and monitoring of the cellular environment, 
and have been widely used for the culture of plant, ani-
mal and microbial cells, and for the production of pro-
teins, antibodies and other biologics conforming to GMP 
standards [11].
Here, the manufacture and release of a cell bank that 
complies with the GMP requirements for a phase 1 
investigational product is described. The cell bank was 
manufactured using a wave bioreactor and consists of 
erythrocytes infected with genetically modified P. falci-
parum parasites. This cost-effective methodology using 
appropriate GMP compliant conditions allows for the 
production of sufficient quantities of material for IBSM 
studies and whole blood-stage vaccine trials, with suf-
ficient material available for quality control and ongo-
ing stability testing. The manufacture of the master cell 
bank was conducted in accordance with the United 
States Food and Drug Administration (FDA) Guidance 
for Industry: CGMP for Phase 1 Investigational Drugs.
Methods
Production of Plasmodium falciparum 3D7‑KAHRP KO GAP 
pre‑seed bank
Genetically attenuated parasites (GAP) were produced 
by targeted deletion of the gene encoding the knob-
associated histidine-rich protein (kahrp) from P. fal-
ciparum strain 3D7, in a similar manner as previously 
described for this and other genes [12, 13]. Briefly, 
deletion of kahrp was achieved by a positive–negative 
selection strategy [14] whereby the entire kahrp gene 
was replaced through double cross-over homologous 
recombination with a cassette encoding human dihy-
drofolate reductase (dhfr), a selectable marker that 
renders transfectants resistant to WR99210 (Jacobus 
Pharmaceuticals, NJ).
The loxP-DHFR-loxP-pCC1 plasmid was created by 
insertion of a loxP-hDHFR-loxP cassette into the pCC1 
plasmid backbone [15], as previously described [16]. 
The KAHRP-KO plasmid was created by cloning kahrp 
5′ and 3′ sequences into this plasmid. Plasmid DNA 
was transfected into P. falciparum 3D7 by electropora-
tion. Following WR positive selection, parasites were 
grown without WR to deselect those containing the 
WR-containing plasmid, thereafter WR was reapplied 
to select those with integration of the dhfr cassette into 
the genome. These were then placed under negative 
selection with 5–fluorocytosine (5-FC; Sigma) to select 
for homologous recombination. 5-FC resistant para-
sites were genotyped by PCR.
KAHRP-KO parasites were cloned by limiting dilu-
tion in 96-well flat bottom plates and the result-
ing clonal line, 3D7-KAHRP-KO, was characterized 
by whole genome sequencing (Accession Number 
PRJEB12838).
The P. falciparum 3D7 parasites used for transfection 
with the kahrp knockout vector were created from the 
3D7 parental strain described previously [17]. This strain 
was used for the original IBSM studies [1] and has been 
extensively used for subsequent studies.
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Production of 3D7‑KAHRP KO GAP seed bank
The GAP seed bank was produced by thawing the con-
tents of one vial of the GAP pre-seed bank following 
a standard protocol [18] and expanding the parasites 
in culture (RPMI 1640 media supplemented with 10% 
heat-treated pooled human serum and 4% human eryth-
rocytes) using standard methods [19]. At each passage, 
fresh complete media and erythrocytes were added and 
the culture was expanded to achieve the required volume 
for cell banking. When the culture contained a mini-
mum of 80% ring-stage parasites at 3–5% parasitaemia, 
the seed bank was cryopreserved using Glycerolyte 57 
(Fenwal Inc.) in a 1:2 ratio, aliquoted into 1  mL cryovi-
als, and stored in vapour phase liquid nitrogen. The final 
GAP seed bank was transferred to a Therapeutic Goods 
Administration (TGA) licensed GMP facility (Q-Gen; 
QIMR Berghofer Medical Research Institute [QIMRB]) 
for further expansion and production of the GAP master 
cell bank.
Production of 3D7 KAHRP‑KO GAP master cell bank
The 3D7 KAHRP-KO GAP master cell bank (GAP MCB) 
was manufactured in a ISO Class 5 Biological Safety Cab-
inet within an ISO Class 7 clean room using tissue cul-
ture flasks and a bioreactor (GE Wave 25™ System). The 
GAP MCB dossier was reviewed by the United States 
Food and Drug Administration (FDA) under the inves-
tigational new drug (IND) program. A summary of the 
process is shown in Fig. 1 and described in detail below.
Parasite thaw and culture in flasks
A vial of the 3D7 KAHRP-KO GAP seed bank was 
thawed at 37 °C with the stepwise addition of 12 and 1.6% 
sodium chloride following a standard protocol [18]. The 
resulting red blood cell (RBC) pellet was washed in 0.9% 
sodium chloride and resuspended in 8  mL of complete 
RPMI-Hepes 1640 media (Life Technologies) containing 
100 µL of 50% haematocrit (HCT) washed RBCs, and the 
cell suspension was transferred to a T25 cm2 flask.
Parasites were cultured in flasks under standard 
malaria culture conditions [19] in an atmosphere of 5% 
carbon dioxide, 5% oxygen and 90% nitrogen at 37 °C and 
media was changed every 24 h. Parasitaemia was moni-
tored by examination of Giemsa-stained thin blood films. 
Additional media and fresh RBCs were added as required 
to maintain the culture at a parasitaemia of between 0.5 
and 4%, and with a 2–5% HCT. The parasite culture was 
expanded to a volume of approximately 100 mL and the 
parasites were synchronized by a single treatment with 
5% sorbitol [20] prior to transfer to a 2 L cellbag of the 
Wave 25™ Bioreactor.
Parasite culture using wave bioreactor
The Ready to Process WAVE 25™ system (GE Health-
care) was used for this study and configuration of the 
equipment is shown in Fig.  2. The system consists of 
a pre-sterile single use cultivation container (cellbag) 
made of FDA approved plastic. Each cellbag has built-
in inlet and outlet air filters, and ports that allow the 
addition of culture medium and extraction of samples 
(Fig.  2a). The cellbag is placed on a temperature-con-
trolled rocking platform (Fig. 2b); gas transfer and mix-
ing of the cell culture is facilitated by movement of the 
rocker unit which induces a wave motion in the culture. 
Temperature, rocking speed, rocking angle and atmos-
pheric conditions (Fig.  2c) are monitored and con-
trolled by the cellbag control unit (CBCU). The system 
is controlled from a PC running UNICORN software 
version 6.3.2 or later.
The synchronous parasite culture was transferred 
into a 2 L cellbag and maintained under conditions con-
trolled electronically by the bioreactor system (Fig. 2c). 
Parasitaemia was monitored by examination of Giemsa-
stained thin blood films. The culture medium was 
changed daily, with washed RBCs added as required to 
maintain a parasitaemia of 0.5–1.2% and a 2–5% HCT. 
When the culture volume reached 500 mL it was trans-
ferred to a 10  L cellbag and the parasite culture was 
expanded to a final volume of approximately 2 L in line 
with the manufacturers recommended culture volumes 
for 2 and 10 L cellbags. To facilitate media change and 
transfer between cellbags the cell culture was removed 
from the in use cellbag under sterile conditions, cen-
trifuged in 250  mL conical bottles (Corning) and the 
supernatant removed. The required volume of fresh 
media was pumped into the destination cell bag under 
the control of the CBC unit and the required volume of 
inoculum added under gravity flow.
The culture was monitored to ensure synchronic-
ity and was maintained such that the % of ring stage 
parasites (as a % of the total parasites) present in the 
culture did not fall below 80%. When the required vol-
ume was reached, the culture was maintained for one 
further invasion cycle before parasites were harvested 
for banking at a parasitaemia target of > 3% and a mini-
mum of 80% ring stage parasites. Progression through 
the final multiplication cycle was monitored by exami-
nation of Giemsa-stained thin blood films every 4–6 h. 
The cell culture supernatant was tested for microbial 
contamination prior to culture in the Wave 25™ Bio-
reactor system and prior to harvesting. At harvest the 
entire cell culture was removed under sterile conditions 
and centrifuged in 250 mL conical bottles to pellet the 
RBCs prior to freezing.
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Culture media
RPMI-Hepes 1640 media (Life Technologies) was sup-
plemented with 10% heat inactivated (HI) pooled human 
serum and hypoxanthine (HT) supplement (0.1  mM 
sodium hypoxanthine and 0.016  mM thymidine). Com-
plete media was used immediately or dispensed in ali-
quots and stored at a temperature of between 2 and 8 °C 
for a maximum of 7 days.
Fig. 1 Process overview. The steps involved in production of the 3D7 KAHRP-KO GAP master cell bank
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a
b
c
Fig. 2 Wave bioreactor configuration. a Each cellbag has built-in inlet and outlet air filters, and ports that allow the addition of culture medium 
and extraction of samples. b The Ready to Process WAVE 25™ system (GE Healthcare) was used for this study. c Temperature, rocking speed, rocking 
angle and atmospheric conditions are monitored and controlled by the cellbag control unit (CBCU)
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The serum used was supplied, screened and tested by 
Key Biologics (Memphis USA), an FDA registered blood 
collection and processing establishment. Whole blood 
units were collected from donors who were screened and 
found acceptable for donation of transfusable blood com-
ponents based on all applicable FDA requirements. Infec-
tious disease testing as required for qualification of blood 
components for transfusion to humans was carried out 
and was required to be non-reactive or negative. Serum 
from individual donors was tested (using FDA approved 
test kits) for human immunodeficiency virus (HIV)-I 
and HIV-II, human T-lymphotropic virus (HTLV) types 
I and II, hepatitis B virus (HBV), hepatitis C virus (HCV), 
Trypanasoma cruzi and syphilis (by serology), and 
underwent nucleic acid testing for HBV, HCV, HIV, and 
West Nile virus (WNV). Serum was then pooled from 
the multiple donors, frozen, stored and shipped under 
controlled conditions to QIMRB. On arrival the serum 
was thawed, heat inactivated at 56 °C, filtered and stored 
at − 20  °C in 50 mL aliquots until required. The pooled 
serum was additionally tested for Epstein Barr virus, Par-
vovirus B19 and herpes virus type 6 by PCR at Pathology 
Queensland. Endotoxin testing and sterility testing was 
performed at Q-Gen.
Leukodepleted packed RBCs (Group O Rh (D) nega-
tive) used for in  vitro cultivation of P. falciparum para-
sites were obtained from the Australian Red Cross Blood 
Service (Blood Service). All supplied RBCs were screened 
according to Blood Service protocols to eliminate indi-
viduals with risk of exposure to transmissible spongiform 
encephalopathy and blood borne agents. The blood was 
collected and leukodepleted at the Blood Service and 
the donor’s blood sample was tested and certified non-
reactive for HIV, HBV, HCV, HTLV and syphilis using 
diagnostic kits approved by the TGA. A blood sample 
was additionally tested by Pathology Queensland for 
infectious diseases that are not included in mandatory 
testing for blood and blood products including anti-Fla-
vivirus IgM antibodies, Trypanasoma cruzi IgG antibod-
ies, Barmah Forest virus IgM and IgG antibodies, and 
Ross River virus IgM and IgG antibodies. Samples were 
also screened (by PCR testing) for Epstein Barr virus 
(EBV), Cytomegalovirus (CMV), Parvovirus B19, Human 
Herpes virus type 6 and type 7(HHV-6 and HHV-7), and 
WNV. On receipt at QIMRB the cells were transferred 
from the Blood Service pack to a sterile container and a 
2 mL aliquot was removed for sterility testing. Aliquots 
of RBCs were washed three times in RPMI and resus-
pended in complete RPMI to give a HCT of 50%. Blood 
was washed as required in aliquots not exceeding 20 mL 
and stored at 2–8 °C for up to 7 days after washing.
Cryopreservation of the GAP MCB
Percentage parasitaemia and parasite life cycle stage were 
assessed by microscopic examination of thin blood films 
and when cultures achieved > 3% parasitaemia with at 
least 80% ring-stage parasites the cell bank was cryopre-
served using Glycerolyte 57 in a 1:2 ratio (i.e. two vol-
umes of Glycerolyte  57 were added to each volume of 
pRBC) as previously described [1].
The cell bank was dispensed in 1 mL aliquots in cryo-
vials, cryopreserved using a controlled rate freezer as 
previously described [8] and stored in vapour phase liq-
uid nitrogen at –196  °C. A total of 200 vials were pro-
duced; two vials were allocated as retention samples. 
The remainder of the cell bank vials were allocated for 
release testing. The release testing of the MCB complied 
with the requirements of the FDA’s Guidance for Indus-
try- Characterization and Qualification of Cell Substrates 
and Other Biological Materials Used in the Production 
of Viral Vaccines for Infectious Disease Indications, the 
United States Pharmacopeia (USP) < 85 > for Bacterial 
Endotoxin Testing, USP < 63 > mycoplasma/spiroplasma 
testing, and the British Pharmacopoeia Appendix XVI 
A: Test for Sterility. The parameters assessed, acceptance 
criteria, test methods and place of testing are listed in 
Table 1.
Parasite viability following cryopreservation
Parasite viability post-freezing was determined by meas-
urement of cloning efficiency via a limiting dilution assay 
[8, 21] with positivity determined by production of P. fal-
ciparum histidine-rich protein II (HRP-II).
In order to determine post-freeze viability, a vial of the 
GAP MCB was thawed following a standard protocol 
[18] and a sample was removed for RBC counting using 
a haemocytometer. The number of parasitized/infected 
RBCs (pRBCs) was determined via microscopic examina-
tion of a Giemsa-stained thin blood smear.
Dilutions of pRBCs were prepared in complete media 
and dispensed in 100  μL aliquots in 96-well flat bot-
tom plates at 2% HCT at theoretical concentrations of 
40, 20, 10, 5, 2.5, 1.25, 0.625 and 0.3125 parasites/well. 
Thirty-two replicates of each concentration were plated 
out and non-parasitized RBCs were included as a nega-
tive control. Plates were incubated in an atmosphere 
of 5%  O2, 5%  CO2 and 90%  N2 at 37  °C for 7  days and 
media was replenished on Day 4. On Day 7, supernatant 
was removed from each well and processed immediately 
or frozen for future testing. The supernatant was tested 
for P. falciparum HRPII using the SD Malaria Antigen Pf 
ELISA kit, according to the manufacturer’s instructions.
Briefly, supernatants from each well were transferred 
to the corresponding well of an uncoated microplate and 
incubated for 15  min following the addition of 150  µL 
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enzyme conjugate (anti-mouse P. falciparum HRP II Ig 
conjugated to horseradish peroxidase in lysis buffer). A 
100  µL sample was then transferred from each well of 
the uncoated microplate to the corresponding well of the 
pre-coated assay microplate and incubated. Plates were 
washed and 100 µL of tetramethylbenzidine substrate 
added to each well. After a 10 min incubation, the reac-
tion was stopped by the addition of 100  µL of 1  mL/L 
(1  N) hydrochloric acid. The absorbance was read at 
450 nm with reference wavelength at 620 nm. The mean 
absorbance values (optical density [OD]) for the positive 
and negative controls were calculated in order to ensure 
the validity of the assay.
The cut off value for parasite positivity was calculated 
using the absorbance values of the 32 two wells con-
taining the RBC negative control. The cut off value was 
the mean plus 3 standard deviations and this value was 
applied to the test samples to calculate the number of 
positive and negative wells. Limiting dilution analysis was 
performed to determine the frequency of viable parasites 
as previously described [22].
In vitro anti‑malarial drug sensitivity testing of the GAP 
MCB
Anti-malarial drug sensitivity testing was carried 
out on the GAP MCB parasites using the standard 
 [3H]-hypoxanthine uptake inhibition assay [23] to ensure 
that the drug resistance phenotype of the parasites had 
not changed during culture. The in  vitro sensitivity of 
the GAP MCB parasites to nine anti-malarial drugs was 
assessed (chloroquine, dihydroartemisinin, piperaquine, 
lumefantrine, amodiaquine, atovaquone, pyronaridine, 
mefloquine, quinine). The parental 3D7 line (chloroquine 
sensitive) and W2 (chloroquine resistant) were included 
as controls. The assays were performed at the Army 
Malaria Institute, Queensland, Australia.
Briefly, aliquots of parasites from the GAP MCB were 
grown in  vitro and synchronized to give 95% ring stage 
parasites. The parasite culture was dispensed into a 
96-well plate containing twofold dilutions of each anti-
malarial drug for testing.  [3H]-hypoxanthine was added 
and the amount incorporated into parasites was meas-
ured after a 48-h incubation. The  IC50 values for each 
drug were determined by nonlinear regression analysis. 
This calculation was performed using GraphPad Prism 
software (GraphPad Prism version 6.00). Drug thresh-
old values were expressed as mean  IC50 (95% confidence 
interval) in nmol/L. The results were compared to pub-
lished threshold values for drug resistance [24].
Genotyping of the GAP MCB
The genotype of the GAP MCB was determined by PCR 
using primers to confirm KAHRP gene deletion and 
hDHFR integration. In vitro culture samples were taken 
at the beginning of the process (Day 0) and at harvest 
(Day 16) and placed in Qiagen lysis buffer. Genomic 
DNA was extracted from paired samples using a Qiagen 
DNAmp DNA Blood Mini Kit and gDNA from the par-
ent strain 3D7 was used as a control. Standard PCR was 
set up using 4 pairs of primers (Table 2) in PCR mix as 
follows:
Mix 1.  Primers mo517 and mo518. No band expected 
when used with gDNA from P. falciparum 3D7 
KAHRP-KO.
Mix 2.  Primers mo517 and Aw560 Presence of a 
1463 bp band expected when used with gDNA 
from P. falciparum 3D7 KAHRP-KO.
Mix 3.  Primers mo519 and mo520 No band expected 
when used with gDNA from P. falciparum 3D7 
KAHRP-KO.
Mix 4.  Primers Aw171 and mo520 Presence of 
1128 bp expected when used with gDNA from 
P. falciparum 3D7 KAHRP-KO.
Amplification of the PCR product was performed using 
Taq DNA polymerase under the following cycling con-
ditions: One initial cycle at 45 °C for 15 min, denaturing 
at 94  °C for 30  s, annealing at 52  °C for 40  s, extension 
at 68 °C for 105 s (30 cycles), one final extension cycle at 
68 °C for 7 min.
Quality check of GAP MCB by qRT‑PCR
To further validate the successful genetic attenuation of 
P. falciparum 3D7 and verify hDHFR integration, a real 
time PCR assay was set up using primers designed at 
various regions of the P. falciparum 3D7 GAP (Fig.  3). 
Primer sequences are listed in Table 2.
To determine limit of detection of possible contami-
nation with wildtype P. falciparum 3D7, two single copy 
genes (pfmdr-1 and pfldh) were amplified and used as 
reference for copy number estimation. A standard curve 
containing five ten-fold serial dilutions of wildtype P. 
falciparum 3D7 was prepared, starting from 2.0  ng/μL 
to amplify KAHRP excised region and MDR1 and LDH 
genes.
Triplicate PCR reactions were set up using the Roche 
Fast Start Essential DNA Green Master Mix (Cat. No. 06 
402 712 001), 10 μM of each primer (Table 2) and 1 μL of 
each gDNA sample in a 12 μL reaction volume. Quantita-
tive PCR was performed using a Roche Light Cycler 96 
with the following cycling conditions: 94 °C for 3 min; 45 
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Table 2 PCR primers used for this study
Oligo name Sequence
Primers used for Genotyping of the GAP MCB
 mo517 GGA ACT CAT TAA TAT GTA TG
 mo518 CAA AAC CCA TAC TAA AAA AG
 mo519 GAG AAC TTT AGC ACA AAA GC
 mo520 TTT ACG CTT TCT GCA TCT TC
 Aw171 CCT AAT CAT GTA AAT CTT AAA TTT TTC 
 Aw560 CCA ATA GAT AAA ATT TGTAG 
Oligo name Sequence Target
Primers used for qRT PCR
 KAHRP-FB CAT ATA GTG CAA TAA TGG AAA CGG A Pf KAHRP gene (inside excised region)
 KAHRP-RB GGT GAT TTA CTT CTC CAT GAT GAT G
 KAHRP-F TGT TCC AGC AGA TGC ACC AA Pf KAHRP gene (in remaining region)
 KAHRP-R GAG CTG AAT AGC CTG CAC CA
 MDR1-T1 F TAT GCA TTT GTG GGA GAA TCAG Pf MDR1 [multi drug resistance] (single copy gene reference)
 MDR1-T1R CTC CTT CGG TTG GAT CAT AAAG 
 hDHFR (FG) ATG CAT GGT TCG CTA AAC T hDHFR [human dihydrofolate reductase] gene
 hDHFR R1 CCA GGT CTT CTT ACC CAT AAT 
 hDHFR FA CCT AAT AGA AAT ATA TCA GGA TCC AT hDHFR (recombination region)
 hDHFR1 R GGT CTT CTT ACC CAT AAT CA
 LDH-T1F AGG ACA ATA TGG ACA CTC CGAT Pf LDH1[lactate dehydrogenase] (single copy gene reference)
 LDH-T1R TTT CAG CTA TGG CTT CAT CAAA 
 Pf SARS F1 AAG TAG CAG GTC ATC GTG Pf SARS [seryl-tRNA synthetase] (housekeeping gene)
 Pf SARS R1 CGG CAC ATT CTT CCATA 
Fig. 3 qRT-PCR primers mapped on KAHRP gene. To validate the successful genetic attenuation of P. falciparum 3D7 and verify hDHFR integration, a 
real time PCR assay was set up using primers designed at various regions of the P. falciparum 3D7 GAP
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cycles of 94 °C for 30 s, 55 °C for 30 s and 68 °C for 30 s, 
and one final extension cycle of 68 °C for 5 min.
Other testing performed on the Gap MCB
A summary of testing performed on the GAP MCB is 
shown in Table  1. Sterility testing complying with the 
requirements of the British Pharmacopoeia (BP) Appen-
dix XVI A: Test for Sterility was carried out using direct 
inoculation as well as testing the supernatant following 
membrane filtration. Endotoxin inhibition testing of the 
GAP MCB and Glycerolyte 57 was performed to comply 
with the requirements of USP < 85 > Bacterial Endotoxin 
Test. Testing for Adventitious Agents complied with the 
requirements outlined in the FDA’s Guidance for Indus-
try: Characterization and Qualification of Cell Substrates 
and Other Biological Materials Used in the Produc-
tion of Viral Vaccines for Infectious Disease Indications. 
Assays for HIV 1 and 2, HTLV I&II, EBV, CMV, HCV, 
HBV, human parvovirus (B19), West Nile virus (WNV), 
adeno-associated virus (AAV), human herpes virus type 
7, human herpes virus type 6 and retroviruses were 
performed in addition to testing for spiroplasma and 
mycoplasma. Sections were examined by quantitative 
transmission electron microscopy for the detection of 
viruses, fungi, yeasts, and bacteria (200 cell profiles). 
In vitro assays for the detection of viral contaminants and 
inapparent viruses was also performed.
Results
A cell bank consisting of erythrocytes infected with 
genetically-modified P. falciparum parasites was success-
fully manufactured using a wave bioreactor. Two hun-
dred vials of the GAP MCB were produced that met the 
requirements for use in Phase I clinical trials.
Growth of P. falciparum 3D7‑KAHRP KO GAP in a bioreactor
GAP parasites maintained an asexual blood stage cycle 
of approximately 39 h during the in vitro culture period 
in the bioreactor, and showed a normal maturation pat-
tern. The percent parasitaemia and percent ring stage 
parasites of the culture over time is illustrated in Fig. 4. 
Parasitaemia was maintained between 0.5 and 2% by the 
addition of RBCs during the expansion phase (Day 0–10). 
During the banking phase (Day 10–15) the parasitaemia 
was maintained below 4%. At harvest the culture had a 
parasitaemia of 6.3%, with 96% of parasites at ring stage 
0
1
2
3
4
5
6
7
0 50 100 150 250 300 350
Fig. 4 Profile of parasitaemia and parasite life cycle stages during growth in biowave reactor system. Parasites maintained an asexual blood stage 
cycle of approximately 39 h during the in vitro culture period, and showed a normal maturation pattern. The percent parasitaemia and percent ring 
stage parasites of the culture over time were determined by microscopy
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(high percentage of ring stage parasites is illustrated in 
Fig.  5). Thus, the pre-defined acceptable criteria of > 3% 
parasitized RBC and ≥ 80% ring stage parasites (Table 1) 
were met.
Identity testing of the GAP MCB
PCR assays confirmed kahrp gene deletion and hDHFR 
integration in parasite samples collected at the initiation 
of culture (Day 0) and at harvest (Day 16) (Fig. 6) dem-
onstrating that the genotype of the parasites was main-
tained during the culture and banking process.
Quality check of Pf KAHRP‑KO by qRT‑PCR
Mean Ct values using primer pairs for KAHRP (inside 
remaining region), hDHFR and recombination region 
were < 31 (positive) using KAHRP-KO gDNA as tem-
plate indicating success of integration. Mean Ct values 
were > 31 (negative) using P. falciparum 3D7 (wildtype) 
gDNA as template. Mean Ct value using primer pairs for 
KAHRP gene (in excised region) was < 31 (positive) only 
for P. falciparum 3D7 (wildtype) gDNA. Mean Ct values 
were > 31 (negative) or undetectable (no Ct) for KAHRP-
KOa and KAHRP-KOb gDNA as templates indicating 
success of deletion in the genetically attenuated parasite.
Amplification of the KAHRP excised region on serially 
diluted wildtype P. falciparum 3D7 and comparing Ct 
values obtained from serially diluted GAP showed unde-
tectable contamination of the GAP starting from 2.0 ng/
μL DNA concentration up to as low as 2.0 × 10−5  ng/
μL. This is equivalent to a single copy or less using single 
copy gene references pfmdr-1 and pfldh.
In vitro drug sensitivity of GAP MCB parasites
The in  vitro sensitivity of the GAP MCB parasites to a 
panel of 9 anti-malarial drugs is shown in Table  3. The 
mean  IC50 (95% confidence interval) results for each drug 
are presented in Table  4 along with the corresponding 
results for the control P. falciparum strains 3D7 and W2.
GAP master cell bank parasites demonstrated sensitiv-
ity to eight of the anti-malarial drugs tested (chloroquine, 
artemisinin, piperaquine, lumefantrine, amodiaquine, 
atovaquone, pyronaridine, quinine) and resistance to 
mefloquine.
Parasite viability of the GAP MCB 
following cryopreservation
Parasite viability was tested using samples taken approxi-
mately 24 h (Time 0) after freezing and at 3 months post-
production. The GAP MCB was determined to contain 
52% viable parasites at Time 0 and 64% viable parasites at 
3 months post-production. These values conform to the 
pre-defined acceptable criteria of > 25% viable parasites. 
The variability between the two time points is within nor-
mally observed limits for this assay.
Discussion
Our aim was to produce a GMP compliant cell bank con-
sisting of KAHRP deficient P. falciparum parasites using 
the wave bioreactor system. Previous studies have shown 
that the wave bioreactor system is suitable for the pro-
duction of large volumes of high quality P. falciparum 
cultures [9]. We have taken this method further to dem-
onstrate that the wave bioreactor can be used to culture 
parasites for use in phase 1 clinical trials.
The use of a wave bioreactor system has a number of 
significant advantages over traditional culture of P. falci-
parum in flasks. Foremost is that it allows close control 
of culture conditions that can be monitored and main-
tained electronically by the wave bioreactor system; the 
cellbags used are single use closed systems approved by 
the FDA. Significant savings in time and labour were also 
achieved; 100 mL of culture was transferred to a cellbag 
on Day 11, expanded to 500  mL on Day 12, and a cul-
ture volume of 2 L was achieved on Day 15 with harvest/
cryopreservation on Day 16. During this rapid expansion 
phase the labour required to maintain the culture (moni-
tor parasitaemia, change media, add fresh RBCs) was 
less than would be required if growing in multiple tis-
sue culture flasks. In addition, the use of multiple flasks 
can result in cultures spending more time in less than 
Fig. 5 Giemsa-stained smear showing GAP MCB parasites at time of 
cryopreservation. At harvest the culture contained a high percentage 
of ring stage parasites
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optimal growth conditions, and increase the probability 
of contamination.
The continual wave motion of the wave bioreactor 
ensures gentle movement of cells in culture resulting in 
a high proportion of single infections [9]. This allows for 
accurate calculation of parasite numbers which is essen-
tial for defined dose delivery in clinical trials. Results 
confirmed that wave bioreactor cultures contained high 
quality ring stage parasites with a low number of multi-
ply infected red cells (< 0.5%). Additionally, the effective 
cryopreservation of the MCB was demonstrated by the 
fact that parasite viability was over 50% after 3 months.
The ability to use research grade starting material, 
including genetically-modified parasites, to produce a 
GMP grade product offers significant opportunities. It 
allows for genetically-modified parasites to be used as 
vaccine candidates and for the number of P. falciparum 
strains available for IBSM studies to be expanded. The 
availability of multiple antigenically and geographically 
diverse P. falciparum strains for IBSM studies is essential 
Fig. 6 Agarose gel showing the genetic identity of the GAP MCB at Days 0 and 16. PCR assays confirmed kahrp gene deletion and hDHFR 
integration in parasite samples collected at the initiation of culture (Day 0) and at harvest (Day 16)
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Table 3 In-vitro drug sensitivity profile of  the  GAP MCB 
parasites
S drug sensitive, R drug resistant
a Insufficient in vivo data to validate in vitro results; no established threshold values
Drug Control Sample
3D7 W2 GAP MCB
Chloroquine S R S
Dihydroartemisinina S S S
Piperaquine S S S
Lumefantrine S S S
Amodiaquine S S S
Atovaquonea S S S
Pyronaridinea S S S
Mefloquine R S R
Quinine S R S
Table 4 Drug threshold values for GAP MCB parasites
Anti‑malarial drug Test 1 Test 2 Test 3
Control Test sample Control Test sample Control Test 
sample
3D7 W2 GAP MCB 3D7 W2 GAP MCB 3D7 W2 GAP 
MCB
CQ (chloroquine)
IC50 (nM) 14.85 206.8 14.37 16.53 297.6 13.77
95% confidence intervals (nM) (8.489–25.98) (131.6–325.0) (8.671–23.80) (9.880–27.64) (179.3–493.9) (8.149–23.28)
DHA (dihydroartemisinin)
IC50 (nM) 5.624 4.354 4.931 7.366 2.019 7.943
95% confidence intervals (nM) (4.271–7.406) (2.902–6.532) (3.667–6.629) (5.600–9.689) (1.539–2.649) (6.065–10.40)
PQ (piperaquine)
IC50 (nM) 18.15 46.02 15.27 30.69 48.85 23.59
95% confidence intervals (nM) (10.41–31.66) (29.78–71.11) (8.490–27.47) (19.33–48.72) (34.94–68.31) (15.29–36.39)
LF (lumefantrine)
IC50 (nM) No results 70.35 No results No results 42.32 No results 315.2 25.31 335.8
95% confidence intervals (nM) (46.35–106.8) (33.26–53.85) (205.2–
484.3)
(18.11–
35.38)
(251.3–
448.7)
AQM (desethylamodiaquine)
IC50 (nM) 10.19 66.83 10.35 18.46 83.88 15.55
95% confidence intervals (nM) (6.031–17.21) (40.88–109.3) (5.551–19.31) (10.06–33.86) (48.10–146.3) (9.139–26.47)
ATQ (atovaquone)
IC50 (nM) 0.9587 1.939 1.147 0.7122 1.524 1.216
95% confidence intervals (nM) (0.8493–1.082) (1.752–2.147) (0.9806–1.342) (0.6224–0.8150) (1.304–1.781) (1.094–1.352)
PD (pyronaridine)
IC50 (nM) 5.398 9.897 7.804 27.67 21.88 12.59
95% confidence intervals (nM) (3.359–8.675) (5.615–17.45) (3.473–17.54) (15.88–48.19) (11.82–40.49) (6.720–23.57)
MQ (mefloquine HCl)
IC50 (nM) 101.5 15.32 98.87 157 12.26 61.27
95% confidence intervals (nM) (72.61–141.8) (10.85–21.65) (69.17–141.3) (79.04–311.8) (8.573–17.53) (43.67–85.96)
QN (quinine HCl)
IC50 (nM) 203.2 795.6 227.4 335.6 569.6 89.73
95% confidence intervals (nM) (169.9–243.0) (527.6–1200) (173.1–298.8) (195.2–577.1) (432.1–750.9) (62.87–128.1)
Drug threshold values are expressed as mean IC50 (95% confidence interval) in nmol/L
The assay was repeated twice and reproducible results were obtained
A third assay was performed for lumefantrine as IC50 values were not detectable in the first two assays
to allow testing of new anti-malarials against multiple 
strains before field testing begins.
The methodology described here is highly cost effec-
tive, with each of the 200 vials produced containing suf-
ficient material for 3600 doses at an approximate cost of 
USD 0.14/dose. Although the method requires use of a 
specialist item of equipment (wave bioreactor system), 
the fact that these units are becoming widely used for a 
range of applications (including tissue engineering, cellu-
lar and gene therapies, the production of therapeutic pro-
teins and human vaccines) means that they are frequently 
available within research facilities or hospitals. The use 
of sterile, single use closed system cell bags means that 
a wave bioreactor system can be shared between groups 
without risk of cross contamination.
Page 14 of 15Pawliw et al. Malar J  (2018) 17:283 
This methodology may represent a cost effective strat-
egy by allowing extensive testing in a controlled envi-
ronment (phase 1 trials) before deciding to move to field 
studies (phase 2 trials) which can be very expensive due 
to logistic and administrative challenges associated with 
carrying out clinical trials in a distant research site. The 
limiting factor for this methodology is that it is currently 
only useful for P. falciparum as other human malaria spe-
cies are not easily grown in vitro.
Conclusion
The large scale in vitro culture of P. falciparum parasites 
using a wave bioreactor can be achieved under GMP 
compliant conditions. This provides a cost-effective 
methodology for the production of malaria parasites suit-
able for administration in clinical trials.
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